Evidence map›Paper›PMID 37026010›Full record

ArticleFrontiers in immunology2023

Identification of common molecular signatures of SARS-CoV-2 infection and its influence on acute kidney injury and chronic kidney disease.

Weiwei Zhang, Leping Liu, Xiangcheng Xiao, Hongshan Zhou, Zhangzhe Peng, Wei Wang, Ling Huang, Yanyun Xie, Hui Xu, Lijian Tao and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. IGF-II regulates lysyl oxidase propeptide and mediates its effects in part via basic helix-loop-helix E40.Matrix biology : journal of the International Society for Matrix Biology · 2024
    Article
  7. Review
  8. Mechanism of transforming growth factor-Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Weiwei ZhangDepartment of Nephrology, Xiangya Hospital of Central South University, Changsha, China.
Leping LiuDepartment of Pediatrics, The Third Xiangya Hospital of Central South University, Changsha, China.
Xiangcheng XiaoDepartment of Nephrology, Xiangya Hospital of Central South University, Changsha, China.
Hongshan ZhouDepartment of Nephrology, Xiangya Hospital of Central South University, Changsha, China.
Zhangzhe PengDepartment of Nephrology, Xiangya Hospital of Central South University, Changsha, China.
Wei WangDepartment of Nephrology, Xiangya Hospital of Central South University, Changsha, China.
Ling HuangDepartment of Nephrology, Xiangya Hospital of Central South University, Changsha, China.
Yanyun XieDepartment of Nephrology, Xiangya Hospital of Central South University, Changsha, China.
Hui XuDepartment of Nephrology, Xiangya Hospital of Central South University, Changsha, China.
Lijian TaoDepartment of Nephrology, Xiangya Hospital of Central South University, Changsha, China.
Wannian NieDepartment of Nephrology, Xiangya Hospital of Central South University, Changsha, China.
Xiangning YuanDepartment of Nephrology, Xiangya Hospital of Central South University, Changsha, China.
Fang LiuHealth Management Center, Xiangya Hospital of Central South University, Changsha, China.
Qiongjing YuanDepartment of Nephrology, Xiangya Hospital of Central South University, Changsha, China.
Central South University · CNXiangya Hospital Central South University · CNThird Xiangya Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the main cause of COVID-19, causing hundreds of millions of confirmed cases and more than 18.2 million deaths worldwide. Acute kidney injury (AKI) is a common complication of COVID-19 that leads to an increase in mortality, especially in intensive care unit (ICU) settings, and chronic kidney disease (CKD) is a high risk factor for COVID-19 and its related mortality. However, the underlying molecular mechanisms among AKI, CKD, and COVID-19 are unclear. Therefore, transcriptome analysis was performed to examine common pathways and molecular biomarkers for AKI, CKD, and COVID-19 in an attempt to understand the association of SARS-CoV-2 infection with AKI and CKD. Three RNA-seq datasets (GSE147507, GSE1563, and GSE66494) from the GEO database were used to detect differentially expressed genes (DEGs) for COVID-19 with AKI and CKD to search for shared pathways and candidate targets. A total of 17 common DEGs were confirmed, and their biological functions and signaling pathways were characterized by enrichment analysis. MAPK signaling, the structural pathway of interleukin 1 (IL-1), and the Toll-like receptor pathway appear to be involved in the occurrence of these diseases. Hub genes identified from the protein-protein interaction (PPI) network, including DUSP6, BHLHE40, RASGRP1, and TAB2, are potential therapeutic targets in COVID-19 with AKI and CKD. Common genes and pathways may play pathogenic roles in these three diseases mainly through the activation of immune inflammation. Networks of transcription factor (TF)-gene, miRNA-gene, and gene-disease interactions from the datasets were also constructed, and key gene regulators influencing the progression of these three diseases were further identified among the DEGs. Moreover, new drug targets were predicted based on these common DEGs, and molecular docking and molecular dynamics (MD) simulations were performed. Finally, a diagnostic model of COVID-19 was established based on these common DEGs. Taken together, the molecular and signaling pathways identified in this study may be related to the mechanisms by which SARS-CoV-2 infection affects renal function. These findings are significant for the effective treatment of COVID-19 in patients with kidney diseases.

Indexed as

Acute Kidney InjuryCOVID-19Renal Insufficiency, ChronicAdaptor Proteins, Signal TransducingHumansMolecular Docking SimulationSARS-CoV-2Adaptor Proteins, Signal TransducingTAB2 protein, humanacute kidney injurychronic kidney diseasedifferentially expressed genesdrug moleculegene ontologyhub geneprotein-protein interactionSARS-CoV-2

Identifiers

PMID37026010
PMCPMC10070855
OpenAlexW4328114014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.